文献速递创伤与烧伤心脑血管急症

院前氨甲环酸与安慰剂对中重度创伤性颅脑损伤患者6个月功能神经结局的影响

Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.
PubMed 文献 · JAMA · 2020-01-01
一句话结论中重度创伤性颅脑损伤患者伤后2小时内院前给予氨甲环酸,与安慰剂相比未显著改善6个月神经功能结局(65% vs 62%,差异3.5%,P=0.16)。

这项多中心、双盲随机临床试验在美国和加拿大20个创伤中心及39个急救医疗服务机构开展,纳入1280例15岁及以上、格拉斯哥昏迷评分≤12且收缩压≥90 mmHg的院前创伤性颅脑损伤患者。干预分为三组:院前氨甲环酸1g弹丸式注射+院内氨甲环酸1g 8小时输注(弹丸维持组,n=312)、院前氨甲环酸2g弹丸式注射+院内安慰剂8小时输注(仅弹丸组,n=345)、院前安慰剂弹丸式注射+院内安慰剂8小时输注(安慰剂组,n=309),均在伤后2小时内启动。主要终点为6个月时良好神经功能(格拉斯哥结局扩展量表评分>4)。分析人群966例中,氨甲环酸组主要终点发生率65% vs 安慰剂组62%(差异3.5%,90%单侧获益置信限-0.9%,P=0.16;97.5%单侧危害置信限10.2%,P=0.84),28天死亡率、6个月残疾评定量表评分及颅内出血进展均无统计学显著差异。

要点

  • 中重度创伤性颅脑损伤患者伤后2小时内院前给予氨甲环酸,6个月良好神经功能65% vs 安慰剂62%,差异3.5%(90%单侧获益置信限-0.9%,P=0.16),未达统计学显著。
  • 28天死亡率氨甲环酸组14% vs 安慰剂组17%,差异-2.9%(95%CI -7.9%至2.1%,P=0.26),无统计学显著差异。
  • 6个月残疾评定量表评分氨甲环酸组6.8 vs 安慰剂组7.6,差异-0.9(95%CI -2.5至0.7,P=0.29),无统计学显著差异。
  • 颅内出血进展氨甲环酸组16% vs 安慰剂组20%,差异-5.4%(95%CI -12.8%至2.1%,P=0.16),无统计学显著差异。
  • 研究采用非对称显著性阈值:获益阈值0.1,危害阈值0.025;主要终点分析基于819例(84.8%)有6个月随访数据的患者。

适用人群与场景

  • 院前创伤性颅脑损伤患者,年龄15岁及以上,格拉斯哥昏迷评分≤12,收缩压≥90 mmHg,伤后2小时内可启动治疗。
  • 研究场景为美国和加拿大20个创伤中心及39个急救医疗服务机构的院前及院内早期阶段。

诊断标准与关键阈值

  • 纳入标准:格拉斯哥昏迷评分≤12分,收缩压≥90 mmHg,年龄≥15岁。
  • 主要终点良好神经功能定义为6个月格拉斯哥结局扩展量表评分>4分(中度残疾或良好恢复)。
  • 获益显著性阈值设为0.1,危害显著性阈值设为0.025。

处置流程与药物剂量

  • 弹丸维持组:院前氨甲环酸1g弹丸式注射,院内氨甲环酸1g 8小时输注(n=312)。
  • 仅弹丸组:院前氨甲环酸2g弹丸式注射,院内安慰剂8小时输注(n=345)。
  • 安慰剂组:院前安慰剂弹丸式注射,院内安慰剂8小时输注(n=309)。
  • 所有治疗均在伤后2小时内启动。

研究设计与关键结果

  • 多中心、双盲、随机临床试验,20个创伤中心和39个急救医疗服务机构,2015年5月至2017年11月,随机1280例,分析人群966例(平均年龄42岁,255例[74%]男性,平均格拉斯哥昏迷评分8分)。
  • 主要终点:氨甲环酸组6个月良好神经功能65% vs 安慰剂组62%,差异3.5%(90%单侧获益置信限-0.9%,P=0.16;97.5%单侧危害置信限10.2%,P=0.84),未达统计学显著。
  • 28天死亡率:氨甲环酸组14% vs 安慰剂组17%,差异-2.9%(95%CI -7.9%至2.1%,P=0.26),无统计学显著差异。
  • 6个月残疾评定量表评分:氨甲环酸组6.8 vs 安慰剂组7.6,差异-0.9(95%CI -2.5至0.7,P=0.29),无统计学显著差异。
  • 颅内出血进展:氨甲环酸组16% vs 安慰剂组20%,差异-5.4%(95%CI -12.8%至2.1%,P=0.16),无统计学显著差异。
  • 819例(84.8%)患者有6个月主要终点随访数据。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于中重度创伤性颅脑损伤患者,伤后2小时内院前给予氨甲环酸(1g弹丸+1g 8小时输注或2g弹丸)与安慰剂相比,未显著改善6个月神经功能结局,作者结论为未显著改善。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Traumatic brain injury (TBI) is the leading cause of death and disability due to trauma. Early administration of tranexamic acid may benefit patients with TBI.

OBJECTIVE: To determine whether tranexamic acid treatment initiated in the out-of-hospital setting within 2 hours of injury improves neurologic outcome in patients with moderate or severe TBI.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency medical services agencies in the US and Canada from May 2015 to November 2017. Eligible participants (N = 1280) included out-of-hospital patients with TBI aged 15 years or older with Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher.

INTERVENTIONS: Three interventions were evaluated, with treatment initiated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309).

MAIN OUTCOMES AND MEASURES: The primary outcome was favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic acid group vs the placebo group. Asymmetric significance thresholds were set at 0.1 for benefit and 0.025 for harm. There were 18 secondary end points, of which 5 are reported in this article: 28-day mortality, 6-month Disability Rating Scale score (range, 0 [no disability] to 30 [death]), progression of intracranial hemorrhage, incidence of seizures, and incidence of thromboembolic events.

RESULTS: Among 1063 participants, a study drug was not administered to 96 randomized participants and 1 participant was excluded, resulting in 966 participants in the analysis population (mean age, 42 years; 255 [74%] male participants; mean Glasgow Coma Scale score, 8). Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month follow-up. The primary outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84). There was no statistically significant difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -0.9 [95% CI, -2.5 to 0.7]; P = .29), or progression of intracranial hemorrhage (16% vs 20%; difference, -5.4% [95% CI, -12.8% to 2.1%]; P = .16).

CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury compared with placebo did not significantly improve 6-month neurologic outcome as measured by the Glasgow Outcome Scale-Extended.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01990768.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020. PMID: 32897344. doi:10.1001/jama.2020.8958

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。